SCHEMBL6404617

SCHEMBL6404617

[CH](c1ncc[nH]1)c1ncc[nH]1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
TLK2 Q86UE8 5/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
NISCH Q9Y2I1 2/20 0.36
MTOR P42345 1/20 0.36
ADK P55263 1/20 0.36
ALOX15 P16050 1/20 0.33
ALOX5 P09917 1/20 0.33
CYP19A1 P11511 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
BRD4 O60885 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL946970 0.79 MTOR (0.45) ALDH1A1SMN1; SMN2NPC1RAB9ATLK2
SCHEMBL17185606 0.78
SCHEMBL25368 0.78
SCHEMBL16924648 0.78 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2NPC1RAB9ATLK2
SCHEMBL444087 0.78
SCHEMBL562917 0.78
SCHEMBL4685302 0.78
SCHEMBL5082 0.78
SCHEMBL2930143 0.78
SCHEMBL7021 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050054662-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054662-A1 Quinazoline derivatives as antitumor agents ERBB2, ERBB3, ABL1 ALDH1A1 3334/4885SMN1; SMN2 4731/4885NPC1 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.